Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush

Go back to Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush

Nightstar Therapeutics plc (NITE) Announces Positive Proof of Concept NSR-RPGR Data

September 24, 2018 6:39 AM EDT

On Saturday, Nightstar Therapeutics plc (NASDAQ: NITE) announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress.

We initiated this study last year, with the anticipation of demonstrating safety and stabilization of disease with NSR-RPGR, our codon-optimized gene therapy for XLRP, said Tuyen Ong, M.D., chief development officer of Nightstar. Based on the preliminary findings of improved visual function as measured by microperimetry, we have established early proof of concept in... More

Nightstar Therapeutics (NITE) PT Raised to $41 at BMO Capital

September 24, 2018 5:42 AM EDT

BMO Capital analyst Matthew Luchini raised the price target on Nightstar Therapeutics (NASDAQ: NITE) to $41.00 (from $30.00) while maintaining a Outperform rating.

... More